Vertex Pharmaceuticals Inc (VRTX) stock
VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3026% above fair value
$538.60−4.02 (-0.74%)
Close on Nov 13, 2026Market cap $136.51BP/E 31.4Yield –
Vertex Pharmaceuticals operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Vertex Pharmaceuticals's operating cash flow for the twelve months ending Jun 30, 2026 was $4.29B, up 11.6% year over year. For fiscal 2025 it was $3.63B. The highest annual figure on record is $4.13B in fiscal 2022.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.63B | – |
| FY2024 | Dec 31, 2024 | -$492.60M | -113.9% |
| FY2023 | Dec 31, 2023 | $3.54B | -14.3% |
| FY2022 | Dec 31, 2022 | $4.13B | +56.2% |
| FY2021 | Dec 31, 2021 | $2.64B | -18.7% |
| FY2020 | Dec 31, 2020 | $3.25B | +107.3% |
| FY2019 | Dec 31, 2019 | $1.57B | +23.5% |
| FY2018 | Dec 31, 2018 | $1.27B | +50.3% |
| FY2017 | Dec 31, 2017 | $844.94M | +257.9% |
| FY2016 | Dec 31, 2016 | $236.10M | – |
| FY2015 | Dec 31, 2015 | -$365.43M | – |
| FY2014 | Dec 31, 2014 | -$573.11M | – |
| FY2013 | Dec 31, 2013 | -$60.67M | -122.7% |
| FY2012 | Dec 31, 2012 | $267.84M | +86.3% |
| FY2011 | Dec 31, 2011 | $143.74M | – |
| FY2010 | Dec 31, 2010 | -$635.44M | – |
| FY2009 | Dec 31, 2009 | -$427.59M | – |
| FY2008 | Dec 31, 2008 | -$226.48M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.13B | +4.9% |
| Q1 FY2026 | Mar 31, 2026 | $1.43B | +74.4% |
| Q4 FY2025 | Dec 31, 2025 | $498.00M | -14.8% |
| Q3 FY2025 | Sep 30, 2025 | $1.24B | -9.4% |
| Q2 FY2025 | Jun 30, 2025 | $1.07B | – |
| Q1 FY2025 | Mar 31, 2025 | $818.90M | -37.3% |
| Q4 FY2024 | Dec 31, 2024 | $584.60M | +149.2% |
| Q3 FY2024 | Sep 30, 2024 | $1.37B | +8.0% |
| Q2 FY2024 | Jun 30, 2024 | -$3.75B | -430.9% |
| Q1 FY2024 | Mar 31, 2024 | $1.31B | +45.2% |
| Q4 FY2023 | Dec 31, 2023 | $234.60M | -78.2% |
| Q3 FY2023 | Sep 30, 2023 | $1.27B | +32.7% |
| Q2 FY2023 | Jun 30, 2023 | $1.13B | -0.5% |
| Q1 FY2023 | Mar 31, 2023 | $899.90M | -5.9% |
| Q4 FY2022 | Dec 31, 2022 | $1.08B | +8.4% |
| Q3 FY2022 | Sep 30, 2022 | $955.50M | +3.1% |
| Q2 FY2022 | Jun 30, 2022 | $1.14B | – |
| Q1 FY2022 | Mar 31, 2022 | $956.20M | +3.8% |
| Q4 FY2021 | Dec 31, 2021 | $995.00M | +102.4% |
| Q3 FY2021 | Sep 30, 2021 | $927.20M | +2.1% |
| Q2 FY2021 | Jun 30, 2021 | -$199.70M | -119.2% |
| Q1 FY2021 | Mar 31, 2021 | $921.00M | +12.9% |
| Q4 FY2020 | Dec 31, 2020 | $491.53M | +10.2% |
| Q3 FY2020 | Sep 30, 2020 | $907.75M | +171.1% |
| Q2 FY2020 | Jun 30, 2020 | $1.04B | +123.9% |
| Q1 FY2020 | Mar 31, 2020 | $815.70M | +151.2% |
| Q4 FY2019 | Dec 31, 2019 | $445.98M | +41.8% |
| Q3 FY2019 | Sep 30, 2019 | $334.79M | -12.2% |
| Q2 FY2019 | Jun 30, 2019 | $463.75M | +44.2% |
| Q1 FY2019 | Mar 31, 2019 | $324.78M | +28.5% |
| Q4 FY2018 | Dec 31, 2018 | $314.58M | +38.3% |
| Q3 FY2018 | Sep 30, 2018 | $381.35M | +124.2% |
| Q2 FY2018 | Jun 30, 2018 | $321.70M | +77.1% |
| Q1 FY2018 | Mar 31, 2018 | $252.66M | -4.9% |
| Q4 FY2017 | Dec 31, 2017 | $227.51M | +57.2% |
| Q3 FY2017 | Sep 30, 2017 | $170.09M | +159.1% |
| Q2 FY2017 | Jun 30, 2017 | $181.65M | – |
| Q1 FY2017 | Mar 31, 2017 | $265.69M | – |
| Q4 FY2016 | Dec 31, 2016 | $144.72M | – |
| Q3 FY2016 | Sep 30, 2016 | $65.66M | – |
See a number that looks wrong?